Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|10|4|311-320

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.10, Iss.4, 2015-10, pp. : 311-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure

By Yoo Changhoon  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1703-1708

Springer Publishing Company

Access to resources Recommend Favorite

Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?

By De Martin Eleonora   Rodriguez-Castro Kryssia I   Vitale Alessandro   Zanus Giacomo   Senzolo Marco   Russo Francesco Paolo   Burra Patrizia  

Future Virology, Vol. 6, Iss. 10, 2011-10 ,pp. : 1179-1186

Future Medicine

Access to resources Recommend Favorite

Digoxin-Specific Antibody Fragments: How Much and When?

By Bateman D. Nicholas  

Adverse Drug Reactions & Toxicological Reviews (now known as Toxicological Reviews), Vol. 23, Iss. 3, 2004-01 ,pp. : 135-143

Adis International

Access to resources Recommend Favorite

How Much Is Too Much?

By COLEMAN WILLIAM P.  

Dermatologic Surgery, Vol. 22, Iss. 11, 1996-11 ,pp. : 978-978

Elsevier

Access to resources Recommend Favorite

License to Kill Tumors: How Much Hope is Justified for Trail?

By  

Current Pharmaceutical Design, Vol. 7, Iss. 16, 2001-11 ,pp. : 1689-1701

Bentham Science Publishers

Access to resources Recommend Favorite